SILENCE THERAPEUTICS

Silence Therapeutics presented strong phase‑II data for Divesiran in polycythaemia vera at the Cantor Fitzgerald Healthcare Conference, with response rates of about 90% (6 mg every 6 weeks) and 88% (6 mg every 12 weeks) and a placebo‑adjusted effect size of nearly 70%. The safety profile remained favorable, and management is preparing discussions with regulators as well as a phase‑III study with roughly 250 patients and a quarterly dosing regimen. After a financing round the company has about USD 272 million in cash (USD 72 million at quarter‑end plus USD 200 million financing) and sees a runway of roughly 2.5–3 years to fund the phase III and selected pipeline projects. Silence notes increasing competition after Rusfertid approval, is exploring commercialization partnerships, and is advancing other programs such as Zerlasiran (ready for phase III) and ANGPTL3. » Więcej na de.investing.com

Silence Therapeutics placed 14,907,407 American Depositary Shares (each ADS = 3 ordinary shares) at $13.50 per ADS, raising gross proceeds of approximately $201.3 million. The syndicate banks fully exercised the overallotment option and sold an additional 1,944,444 ADS. Jefferies, Morgan Stanley, Cantor and William Blair led the transaction, which was based on a registration statement that became effective on May 27, 2026. » Więcej na de.investing.com

Silence Therapeutics’ share slipped in premarket trading after about 12.96 million American Depositary Shares were placed at $13.50; gross proceeds are reported at roughly $175 million before fees. The syndicate banks have a 30‑day option for up to 1.94 million additional ADS, which could mean further dilution. Positive drivers included phase‑2 topline data from the SANRECO study and Morgan Stanley’s confirmation of an “Overweight” rating with an increased $32 price target. The narrower net result in Q2 year‑on‑year was accompanied by weaker revenue, so the short‑term pressure on the share price is mainly due to dilution caused by the offering discount. » Więcej na de.investing.com